company background image
CRSP

CRISPR Therapeutics NasdaqGM:CRSP Stock Report

Last Price

US$55.51

Market Cap

US$4.3b

7D

8.8%

1Y

-9.1%

Updated

07 Feb, 2023

Data

Company Financials +

CRSP Stock Overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

CRSP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

CRISPR Therapeutics AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CRISPR Therapeutics
Historical stock prices
Current Share PriceUS$55.51
52 Week HighUS$86.95
52 Week LowUS$38.94
Beta1.65
1 Month Change17.58%
3 Month Change13.45%
1 Year Change-9.06%
3 Year Change-2.61%
5 Year Change38.39%
Change since IPO293.97%

Recent News & Updates

Recent updates

Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

Dec 08
Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag

Sep 28

Crispr: Elucidating And Forecasting Key Developments

Sep 21

Crispr Therapeutics: Nearing Harvest Season

Sep 08

Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)

Aug 25

News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts

Aug 09
News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts

CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M

Aug 08

Crispr Therapeutics' Continued Progress Warrants A Buy

Jul 25

Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term

Jun 23

Crispr Therapeutics: Progress, Risk, And Reward

Apr 27

The Commercial Potential Of Crispr In Light Of Patent Challenges

Mar 22

Bad News may be Good for Long Term Investors - Analyzing the Key Risks of CRISPR Therapeutics AG (NASDAQ:CRSP)

Mar 10
Bad News may be Good for Long Term Investors - Analyzing the Key Risks of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics - Progress Adds More Value Than Patent Setback Subtracts

Mar 03

CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 02
CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 99% Above Its Share Price

Crispr Therapeutics' Giant Leap For Humankind

Jan 14

Crispr Therapeutics: Buy The Dip On Promise Of Vertex Collaboration

Dec 15

Crispr Therapeutics: An Interesting Company That Has Reconnected With A Fair Valuation

Dec 02

CRISPR's Life-Saving Technology Has Massive Potential

Nov 22

Crispr Therapeutics: The Future Of Gene Therapy

Oct 15

Crispr: Bad News For Gene Editing

Sep 18

Crispr Therapeutics: Lucrative Partnerships And Promising Data Increase Its Appeal

Aug 28

Do CRISPR Therapeutics's (NASDAQ:CRSP) Earnings Warrant Your Attention?

Aug 04
Do CRISPR Therapeutics's (NASDAQ:CRSP) Earnings Warrant Your Attention?

Crispr Therapeutics: Get Ready To Bail Out

Jul 05

CRISPR Therapeutics and Capsida Biotherapeutics ink strategic collaboration agreement

Jun 15

Here's Why Shareholders May Want To Be Cautious With Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Pay Packet

Jun 04
Here's Why Shareholders May Want To Be Cautious With Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Pay Packet

CRISPR: First Cut Has Deepest Value - Buy And Hold

May 31

Intellia and Sangamo preferred as RBC extends gene editing coverage

May 04

We're Hopeful That CRISPR Therapeutics (NASDAQ:CRSP) Will Use Its Cash Wisely

Apr 29
We're Hopeful That CRISPR Therapeutics (NASDAQ:CRSP) Will Use Its Cash Wisely

Crispr Therapeutics: Strong Partnership And Data Development

Apr 26

How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?

Mar 14
How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?

Investors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares Three Years Ago Are Now Up 411%

Jan 20
Investors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares Three Years Ago Are Now Up 411%

CRISPR Is The Future Of Medicine, And CRSP Is One Stock To Own

Dec 22

Need To Know: Analysts Are Much More Bullish On CRISPR Therapeutics AG (NASDAQ:CRSP) Revenues

Dec 16
Need To Know: Analysts Are Much More Bullish On CRISPR Therapeutics AG (NASDAQ:CRSP) Revenues

CRISPR Therapeutics enters into a share sale agreement with Jefferies

Dec 11

Shareholder Returns

CRSPUS BiotechsUS Market
7D8.8%-0.8%0.9%
1Y-9.1%3.9%-10.9%

Return vs Industry: CRSP underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: CRSP exceeded the US Market which returned -10.9% over the past year.

Price Volatility

Is CRSP's price volatile compared to industry and market?
CRSP volatility
CRSP Average Weekly Movement8.6%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CRSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CRSP's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013473Sam Kulkarnihttps://www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
CRSP fundamental statistics
Market CapUS$4.35b
Earnings (TTM)-US$680.85m
Revenue (TTM)US$14.09m

308.4x

P/S Ratio

-6.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRSP income statement (TTM)
RevenueUS$14.09m
Cost of RevenueUS$593.32m
Gross Profit-US$579.23m
Other ExpensesUS$101.62m
Earnings-US$680.85m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-8.70
Gross Margin-4,110.66%
Net Profit Margin-4,831.79%
Debt/Equity Ratio0%

How did CRSP perform over the long term?

See historical performance and comparison